March 06, 2021
5 min watch
Save
VIDEO: Tyrosine kinase inhibitor implant performs well in phase 1 study for wet AMD
In this video, Andrew A. Moshfeghi, MD, MBA, discusses results from a phase 1 study of an intravitreal hydrogel axitinib implant for wet AMD he recently presented at the virtual Angiogenesis, Exudation, and Degeneration meeting.
OTX-TKI from Ocular Therapeutix showed good safety, tolerability and efficacy.